title: [Clinical significance of neutrophil to lymphocyte ratio in colorectal cancer patients receiving adjuvant chemotherapy combined with polysaccharide-K].
abstract: The neutrophil to lymphocyte ratio (N/L ratio) has been reported to be related to the prognosis of various types of cancer. In particular, a high N/L ratio has been suggested to be associated with poor outcome. We investigated the changes in N/L ratio during treatment in 12 patients who had undergone surgery for colorectal cancer and were receiving postoperative adjuvant therapy with a combination of chemotherapy and polysaccharide-K (PSK). The patients were stratified into 2 groups according to the preoperative N/L ratio (cut-off ratio was 2.5): high N/L (≥2.5) and low N/L (<2.5). The changes in N/L ratio and other clinical parameters over time were investigated. In patients with a high preoperative N/L ratio, the use of postoperative PSK-chemotherapy controlled the N/L ratio at low levels. The N/L ratio tended to remain low in patients with low preoperative N/L ratios. No difference in outcome was observed between patients with high and low N/L ratios. In patients who underwent colorectal cancer surgery, postoperative adjuvant therapy with a combination of chemotherapy and PSK succeeded in controlling the N/L ratio at low levels. Further studies with more patients are required to explore the outcomes associated with changing N/L ratios.
authors.affiliation: Dept. of Surgery, Hyogo Prefectural Nishinomiya Hospital.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Yoshioka
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kubo
authors.forename: Kiminori
authors.initials: K
authors.lastname: Yanagisawa
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Hata
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takiuchi
authors.forename: Rie
authors.initials: R
authors.lastname: Hamano
authors.forename: Junya
authors.initials: J
authors.lastname: Minohata
authors.forename: Masaki
authors.initials: M
authors.lastname: Kashiwazaki
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Miki
authors.forename: Masaki
authors.initials: M
authors.lastname: Tsujie
authors.forename: Muneharu
authors.initials: M
authors.lastname: Konishi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yano
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D011134:Polysaccharides / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D011134:Polysaccharides